Can-Fite Initiates Reverse Split to Bolster NYSE American Listing
Event summary
- Can-Fite BioPharma Ltd. approved a 1-for-3,000 reverse stock split of its ordinary shares, effective January 2, 2026, on the Tel-Aviv Stock Exchange.
- The company will simultaneously adjust the ADS ratio from 300 ordinary shares per ADS to 2 ordinary shares per ADS, effective January 5, 2026, on the NYSE American.
- This change is equivalent to a 1-for-20 split for ADS holders, requiring an exchange of 20 ADSs for 1 new ADS.
- The reverse split will reduce the total number of outstanding ordinary shares to approximately 500,000 and decrease the authorized number of ordinary shares from 42 billion to 14 billion.
The big picture
The reverse split signals a strategic effort by Can-Fite to improve its visibility and attractiveness to US investors, likely driven by a desire to meet minimum listing requirements and potentially increase its share price. This move is a common tactic for companies facing low share prices, but its long-term success hinges on underlying business performance and clinical trial outcomes. The change in ADS ratio also suggests a desire to make the stock more accessible to a broader range of investors.
What we're watching
- Price Volatility
- The immediate impact on the ADS price will be closely watched, as the market assesses whether it reaches the anticipated 20x multiple or experiences a correction.
- Trading Volume
- Reduced share count could lead to lower trading volume and liquidity, potentially impacting institutional investor interest and price discovery.
- Listing Compliance
- Can-Fite must maintain compliance with NYSE American listing requirements, and the reverse split is likely intended to support this effort, requiring ongoing monitoring of share price and trading metrics.
Related topics